Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Solasia Pharma KK's revenue for the
three
months ended in Mar. 2026 was €0.03 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was €2.03 Mil.
Solasia Pharma KK's Revenue per Share for the
three
months ended in Mar. 2026 was €0.00.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €0.01.
Warning Sign:
Solasia Pharma KK revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Solasia Pharma KK was 187.80% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -39.00% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -21.00% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -13.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Solasia Pharma KK's highest 3-Year average Revenue per Share Growth Rate was 227.40% per year. The lowest was -39.00% per year. And the median was -8.10% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Solasia Pharma KK Revenue Related Terms
Solasia Pharma KK Revenue Historical Data
* Premium members only.
The historical data trend for Solasia Pharma KK's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Solasia Pharma KK's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Solasia Pharma KK Revenue vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Solasia Pharma KK's Revenue distribution charts can be found below:
* The bar in red indicates where Solasia Pharma KK's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.03 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Solasia Pharma KK (FRA:9SO) has a Revenue of €2.03 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Solasia Pharma KK and its competitors.
Is Solasia Pharma KK's Revenue too high?
Solasia Pharma KK's current Revenue is €2.03 Mil. Overall, Solasia Pharma KK has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Solasia Pharma KK's Revenue compare to ZTS?
Solasia Pharma KK's Revenue of €2.03 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Drug Manufacturers company?
A good Revenue depends on the Drug Manufacturers industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Solasia Pharma KK and its competitors. Solasia Pharma KK's current Revenue is €2.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solasia Pharma KK stock overvalued right now?
Based on GuruFocus' analysis, Solasia Pharma KK (FRA:9SO) is currently considered Fairly Valued. The stock's GF Value™ is €0.13, compared to a current price of €0.13 — trading 1.5% below its estimated fair value. The current Revenue is €2.03 Mil. Solasia Pharma KK's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Solasia Pharma KK (FRA:9SO), the current Revenue is €2.03 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Solasia Pharma KK (FRA:9SO) Overvalued in 2026?
Based on GuruFocus' analysis, Solasia Pharma KK stock appears to be undervalued.
The current stock price of €0.13 is trading 1.5% below its estimated GF Value™ of €0.13.
GuruFocus considers Solasia Pharma KK to be Fairly Valued.
Key valuation signals for FRA:9SO:
Revenue: €2.03 Mil
GF Value™: €0.13 vs. price of €0.13 (1.5% below fair value)
No single metric tells the full story. See the FRA:9SO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:9SO has been successfully added to your 
